Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey

Czech version

Authors: Michal Vrablík ¹; Zdeněk Chmelík ¹; Věra Lánská ²
Authors‘ workplace: III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA ¹; IKEM Praha, ředitel MUDr. Aleš Herman, Ph. D. ²
Published in: Vnitř Lék 2014; 60(11): 991-997
Category: Reviews

Overview

Background:
Cardiovascular (CV) disease belongs to the most important mortality causes worldwide. Early identification of risk factors and increased CV risk may help decrease of morbidity and mortality. An optimal age for CV risk factors screening ages of 40 in males and of 50 in females have been identified. CV risk profile of persons in these age categories has been examined by general practitioners and recorded for the purposes of this cross-sectional survey.

Methods:
1812 persons, males at average age of 40 years and females at average age of 50 years, were included into the survey. In each of the examined family and personal history including pharmacological were recorded into the study protocol as well as abusus and physical activity patterns. Basic anthropometrical parameters, e.g. heart rate, blood pressure, body mass index and laboratory measures including blood lipids and glycaemia. The participating physicians recorded newly identified risk factors CV disease and determined the global CVD risk according to the SCORE charts. Percentage of those already treated for any of the main CVD risk factors and, among these, also attaining the treatment goals. The percentage of patients with a newly identified CV risk factor was calculated. We also tested the hypothesis of a relationship between positive family history of any of the followed risk factors and its risk in the examined probands using Pearson´s test.

Results:
961 males, average age of 42.9 ± 4.7 years, and 851 females , average age of 51.2 ± 3.6 years, were enrolled into the study. 49% of males and 31% of females were overweight and 32% men and 31% of women were obese. There were 36% of smokers among men and 22% among women. The prevalence of type 2 diabetes was 11% in males and also in females. Arterial hypertension was diagnosed in 43% of males and 45% of females while dyslipidemia was present in 39% of males and 41% of females. Pharmacological treatment of any of the above mentioned diseases was used in 48% of the probands, however, only 7% of them attained treatment goals of blood pressure, LDL-cholesterol and glycaemia. Type 2 diabetes was newly identified in 3% of both males and females, arterial hypertension in 8% of males and 5% of females and dyslipidemia was newly detected in 20% of probands of both genders. Non-pharmacological treatment was recommended to 62% of male and to 65% of female participants, respectively. Pharmacological treatment was initiated in 53% of males and 51% of females. In both genders this was mostly antihypertensive treatment with ACE inhibitors (29% of males and 24% of females) and lipid lowering therapy with a statin (29% of males, 27% females). The analysis of relationship between the positive family history of any of the followed diseases and their presence in the probands examined revealed significant increases of the risk for arterial hypertension, type 2 diabetes mellitus and dyslipidemia.

Conclusion:
The survey following CV risk profile in a cohort of 40 years old men and 50 years old women showed high prevalence of CV risk factors in these age categories in the Czech probands. The high frequency of modifiable risk factors and the need to initiate pharmacological treatment in more than one half of the examined population documents the need of early detection of risk. Genetic determination of individual major risk factors for CVD mirrored in the positive family history represents an important component of the global cardiovascular risk and must be actively detected and taken into account for the risk stratification.

Key words:
cardiovascular risk – dyslipidemia – family history – hypertension – obesity – risk factors – screening – type 2 diabetes

Sources

1. Černy J, Hradec J, Roztočil K. Národní kardiovaskulární program, 2000, [citováno 12.11.2014]; dostupné na World Wide Web: http.//www.kardio-cz.cz .

2. Hopkins PN, Williams RR. Identification and relative weight of cardiovascular risk factors. Cardiol clin 1986; 4(1): 3–31

3. Fait T, Vrablík M, Češka R et al. Preventivní medicína 2. vyd. Praha: Maxdorf Jesenius 2011: 162

4. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008 May 15;358(20):2107–16

5. Yusuf S, Hawken S, Ounpuu S; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438):937–52.

6. Fruchart JC, Sacks FM, Hermans MP et al. The residual risk initiative: a call to action to reduce residual vascular risk in dyslipideamic patients. Diabetes Vasc Dis Res 2008, 5: 319–335

7. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012); Th e Fift h Joint Task Force of the ESC and other Societies on Cardiovascular Disese Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts): Eur Heart 2012 doi.10.1093/eurheartj/ehs092.

8. Catapano AL, Reiner Z, Backer GD et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Aterosclerosis Society (EAS). Aterosclerosis 2011;217:3–46

9. Cífková R, Škodová Z, Bruthans J et al. Longitudinal trends in cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 211 (2010) 676–681.

10. Mayer O Jr., Bruthans J, Timoracká K, on behalf of Czech EUROASPIRE I–IV investigators, The changes in cardiovascular prevention practice between 1995 and 2012 in the Czech Republic. A comparison of EUROASPIRE I, II, III and IV study, Cor et Vasa 2014;56:e91–e97.

11. Péče o nemocné cukrovkou 2012. UZIS 2013, dostupné na www. uzis.cz

12. Filipovský J, Widimský J Jr., Ceral J, Cífk ová R, Horký K, Linhart A, Monhart V, Rosolová H, Seidlerová J, Souček M,Špinar J, Vítovec J, Widimský J. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012;58:785–801.

13. Cífková R, Horký K, Widimský J Sr. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2004. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2014; 50:709–722.

14. Bruthans J, Cífková R, Lánská V et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol. 2012 Nov 24;21(7):829–839.

15. Vrablík M et al. Otazníky kardiovaskulární prevence 2009. FAMA, Brno, 2009, s. 189

16. Cifkova R et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Supplementum Cor Vasa 2005; 47(9): 3–14

17. UZIS Evropské výběrové šetření o zdravotním stavu v ČR – EHIS CR Index tělesné hmostnosti, fyzická aktivita, spotřeba ovoce a zeleniny, Aktuální informace 70, 2010, [citováno 12.11.2014],dotupné na World Wide Web: http://www.uzis.cz/rychle-informace/evropske-vyberova-setreni-zdravotnim-stavu-cr-ehis-cr-index-telesne-hmotnosti-fyzic)

18. Rosa J, Zelinka T, Petrak O et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? Journal of Human Hypertension 2014; 28: 684–688.

19. Vrablík M. Adherence a jak ji ovlivnit. Med. praxi 2013; 10(11, 12): 364–366

20. Soška V, Vaverková H, Vrablík M et al. stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011. DMEV 2013, 16: 24–29.

21. Piťha J et al. Vliv pozitivní rodinné anamnézy na věk manifestace akutního koronárního syndromu a na kardiovaskulární rizikové faktory u žen. 17. výroční sjezd ČKS, 10. – 13. května 2009, Brno. Cor et Vasa. (suppl. č.1): s.; 2009.